IRIDEX Corporation

Equities

IRIX

US4626841013

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-04-17 pm EDT 5-day change 1st Jan Change
3.18 USD -2.75% Intraday chart for IRIDEX Corporation -1.55% +13.17%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : IRIDEX Corporation, Q4 2023 Earnings Call, Mar 26, 2024
Earnings Flash (IRIX) IRIDEX CORPORATION Reports Q4 Revenue $12.5M, vs. Street Est of $14.9M MT
IRIDEX Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
IRIDEX Corporation Reports Earnings Results for the Fourth Quarter Ended December 30, 2023 CI
North American Morning Briefing : Markets Steady -2- DJ
Iridex Corporation Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust CI
Iridex Corporation Launches New Iridex 532 and Iridex 577 Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma CI
Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation CI
Transcript : IRIDEX Corporation, Q3 2023 Earnings Call, Nov 14, 2023
Earnings Flash (IRIX) IRIDEX CORPORATION Reports Q3 Revenue $12.9M, vs. Street Est of $13.5M MT
IRIDEX Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
IRIDEX Corporation Withdraws Previously Announced Guidance for 2023 CI
Wall Street Set to Open Mixed Ahead of Federal Reserve Meeting MT
IRIDEX Hires Advisers to Explore Strategic Alternatives MT
Iridex Announces Strategic Review to Unlock Shareholder Value CI
Transcript : IRIDEX Corporation, Q2 2023 Earnings Call, Aug 10, 2023
IRIDEX Corporation Reports Earnings Results for the Second Quarter and Six Months Ended July 01, 2023 CI
Earnings Flash (IRIX) IRIDEX CORPORATION Reports Q2 Revenue $12.9M, vs. Street Est of $14.2M MT
IRIDEX Corporation Provides Revenue Guidance for the Year 2023 CI
IRIDEX Corporation(NasdaqGM:IRIX) dropped from Russell Microcap Value Index CI
IRIDEX Corporation(NasdaqGM:IRIX) dropped from Russell 3000E Value Index CI
Transcript : IRIDEX Corporation, Q1 2023 Earnings Call, May 11, 2023
IRIDEX Corporation Reports Earnings Results for the First Quarter Ended April 01, 2023 CI
Earnings Flash (IRIX) IRIDEX CORPORATION Reports Q1 Revenue $13.7M, vs. Street Est of $13.6M MT
IRIDEX Corporation Reiterates Financial Guidance for 2023 CI
Chart IRIDEX Corporation
More charts
IRIDEX Corporation is an ophthalmic medical technology company. It develops and commercializes products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probes products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3.18 USD
Average target price
2 USD
Spread / Average Target
-37.11%
Consensus
  1. Stock Market
  2. Equities
  3. IRIX Stock
  4. News IRIDEX Corporation
  5. IRIDEX Sees Q4 2021 Revenue at $15.1 Million to $15.3 Million, Ahead of Street Estimates; Shares Rise